City
Epaper

Pakistan approves Chinese Sinopharm COVID -19 vaccine for emergency use

By ANI | Updated: January 19, 2021 09:35 IST

The Drug Regulatory Authority of Pakistan (Drap) on Monday approved Chinese state-owned firm Sinopharm's COVID-19 vaccine for emergency use, the second vaccine to be given approval for use in the country, reported Dawn.

Open in App

The Drug Regulatory Authority of Pakistan (Drap) on Monday approved Chinese state-owned firm Sinopharm's COVID-19 vaccine for emergency use, the second vaccine to be given approval for use in the country, reported Dawn.

Earlier, on Friday Drap had authorised the Oxford University-AstraZeneca COVID-19 vaccine for emergency use in Pakistan.

"In a meeting conducted by [the] Registration Board of Drap today January 18, 2021, another vaccine manufactured by China National Pharmaceutical Group (Sinopharm) has also been given EUA (emergency use authorisation)," a spokesperson for the regulatory body said in a statement.

Both the Oxford and Sinopharm vaccines were evaluated for their safety and quality and granted EUA "with certain conditions", the statement added.

"This authorisation will be reviewed on a quarterly basis keeping in view further data regarding safety, efficacy and quality," it said.

Sinopharm is developed by the Beijing Institute of Biological Products, a state-owned subsidiary conglomerate. The company had claimed the efficacy rate to be 79.3 per cent from last-stage trials, reported Dawn.

Meanwhile, China had approved the Sinopharm vaccine for general use in the last month itself. Also, it can be stored at two to eight degrees Celsius, or a normal refrigeration temperature.

It is also been approved in the UAE and Bahrain and is slated for use in Morocco too, reported Dawn.

It is an inactive vaccine, which means the virus was grown in a lab and then killed. The germ is then injected into the body to generate an immune response.

The final proof of the two-dose vaccine's effectiveness will depend on the publication of more data, reported Dawn.

Earlier, on December 30, a special cabinet committee for procurement of COVID-19 vaccine, chaired by Federal Minister for Planning and Development Asad Umar, had decided to procure 1.1 million doses of vaccine from Sinopharm. It was also announced that the vaccine would be provided to 500,000 frontline healthcare workers as two doses would be given to each worker and the margin of spoilage was 10 per cent.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Drug regulatory authoritySinopharmpakistanOxfordDhs punjab
Open in App

Related Stories

NationalChandigarh BJP Office Blast: Two Suspects Arrested for Grenade Blast; Drone Used to Smuggle Chinese Hand Grenade From Pakistan

InternationalUS State Department Announces Permanent Closure of Peshawar Consulate in Pakistan

InternationalSaudi Arabia Destroys 21 Drones, 3 Ballistic Missiles in First Week of Middle East War

InternationalMiddle East Crisis: Saudi Arabia-Pakistan to Take Joint Military Action Against Iran Attacks in KSA?

CricketPakistan Player Misbehaved With Hotel Staff During T20 World Cup 2026

International Realted Stories

International90 minutes before self-imposed deadline, Trump pulls back from Iran brink

InternationalIran's 10-point proposal in negotiations with US

International"Productive meeting on US-India commercial roadmap": Sergio Gor meets US Commerce Secretary

International"Both parties displayed remarkable wisdom": Pakistan welcomes US-Iran ceasefire

InternationalUS sees stable China trade, flags WTO crisis